2seventy bio, Inc. (TSVT)
- Previous Close
4.7700 - Open
4.4900 - Bid 4.2700 x 100
- Ask 4.3800 x 200
- Day's Range
4.2800 - 4.5100 - 52 Week Range
1.5350 - 6.4000 - Volume
418,005 - Avg. Volume
400,774 - Market Cap (intraday)
222.986M - Beta (5Y Monthly) 1.78
- PE Ratio (TTM)
-- - EPS (TTM)
-3.0600 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.75
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
www.2seventybio.comRecent News: TSVT
View More
Performance Overview: TSVT
Trailing total returns as of 9/25/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TSVT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TSVT
View MoreValuation Measures
Market Cap
245.13M
Enterprise Value
294.65M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.25
Price/Book (mrq)
1.04
Enterprise Value/Revenue
6.68
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.01%
Return on Equity (ttm)
-51.89%
Revenue (ttm)
44.12M
Net Income Avi to Common (ttm)
-156.25M
Diluted EPS (ttm)
-3.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
201.87M
Total Debt/Equity (mrq)
107.07%
Levered Free Cash Flow (ttm)
-84.92M
Research Analysis: TSVT
View MoreCompany Insights: TSVT
TSVT does not have Company Insights